JP2017527561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527561A5 JP2017527561A5 JP2017512320A JP2017512320A JP2017527561A5 JP 2017527561 A5 JP2017527561 A5 JP 2017527561A5 JP 2017512320 A JP2017512320 A JP 2017512320A JP 2017512320 A JP2017512320 A JP 2017512320A JP 2017527561 A5 JP2017527561 A5 JP 2017527561A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- formula
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 54
- 150000003839 salts Chemical class 0.000 claims 54
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- -1 4- (methylsulfonyl) phenyl Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072573A JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046842P | 2014-09-05 | 2014-09-05 | |
| US62/046,842 | 2014-09-05 | ||
| PCT/US2015/048429 WO2016037005A1 (en) | 2014-09-05 | 2015-09-03 | Inhibitors of lysine specific demethylase-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072573A Division JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527561A JP2017527561A (ja) | 2017-09-21 |
| JP2017527561A5 true JP2017527561A5 (enExample) | 2018-10-18 |
| JP6692350B2 JP6692350B2 (ja) | 2020-05-13 |
Family
ID=55440376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512320A Expired - Fee Related JP6692350B2 (ja) | 2014-09-05 | 2015-09-03 | リジン特異的なデメチラーゼ−１の阻害剤 |
| JP2020072573A Expired - Fee Related JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072573A Expired - Fee Related JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9822119B2 (enExample) |
| EP (1) | EP3189038B1 (enExample) |
| JP (2) | JP6692350B2 (enExample) |
| KR (1) | KR102476459B1 (enExample) |
| CN (2) | CN107074787B (enExample) |
| AU (2) | AU2015311805B2 (enExample) |
| BR (1) | BR112017004334A2 (enExample) |
| CA (1) | CA2960188A1 (enExample) |
| CL (1) | CL2017000521A1 (enExample) |
| CO (1) | CO2017002191A2 (enExample) |
| EA (1) | EA201790376A1 (enExample) |
| EC (1) | ECSP17013466A (enExample) |
| ES (1) | ES2935114T3 (enExample) |
| IL (1) | IL250876B (enExample) |
| MX (1) | MX381597B (enExample) |
| SG (2) | SG10202008486SA (enExample) |
| WO (1) | WO2016037005A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102476459B1 (ko) * | 2014-09-05 | 2022-12-09 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| KR20180011331A (ko) | 2015-06-12 | 2018-01-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제와 관련된 바이오마커 및 그의 용도 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017079476A1 (en) | 2015-11-05 | 2017-05-11 | Mirati Therapeutics, Inc. | Lsd1 inhibitors |
| TWI679195B (zh) | 2015-11-27 | 2019-12-11 | 日商大鵬藥品工業股份有限公司 | 新穎聯苯化合物或其鹽 |
| MX384792B (es) | 2015-12-29 | 2025-03-14 | Mirati Therapeutics Inc | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). |
| WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN105924397B (zh) * | 2016-04-29 | 2017-11-24 | 河南省农业科学院植物保护研究所 | 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途 |
| MA45189A (fr) * | 2016-06-07 | 2019-04-10 | Jacobio Pharmaceuticals Co Ltd | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 |
| CN116478132A (zh) * | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| TWI770925B (zh) * | 2017-05-26 | 2022-07-11 | 日商大鵬藥品工業股份有限公司 | 使用有新穎聯苯化合物之抗腫瘤效果增強劑 |
| CN110740991B (zh) * | 2017-05-26 | 2023-07-04 | 大鹏药品工业株式会社 | 新型联苯化合物或其盐 |
| TWI749235B (zh) | 2017-05-31 | 2021-12-11 | 日商大鵬藥品工業股份有限公司 | 基於insm1表現之lsd1抑制劑之治療效果的預測方法 |
| CN110996949A (zh) | 2017-08-03 | 2020-04-10 | 奥瑞泽恩基因组学股份有限公司 | 用于治疗行为改变的方法 |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| JP7536316B2 (ja) | 2019-03-20 | 2024-08-20 | オリソン ヘノミクス，ソシエダ アノニマ | 境界性パーソナリティ障害の処置方法 |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| US12447171B2 (en) | 2019-06-20 | 2025-10-21 | Celgene Quanticel Research, Inc. | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| EP4058151B1 (en) | 2019-11-13 | 2025-05-21 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| CN117015540A (zh) * | 2021-03-11 | 2023-11-07 | 南京明德新药研发有限公司 | 噻吩类化合物及其应用 |
| WO2022199662A1 (zh) * | 2021-03-24 | 2022-09-29 | 四川汇宇制药股份有限公司 | 一种多环化合物及其应用 |
| WO2022214303A1 (en) | 2021-04-08 | 2022-10-13 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| US20250032454A1 (en) * | 2021-10-18 | 2025-01-30 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
| CN118206499A (zh) * | 2021-11-29 | 2024-06-18 | 郑州大学 | 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用 |
| CN117157288A (zh) * | 2022-01-25 | 2023-12-01 | 成都苑东生物制药股份有限公司 | 一种吡啶类衍生物、其制备方法及用途 |
| CN116836167B (zh) * | 2022-03-25 | 2025-09-09 | 腾讯科技（深圳）有限公司 | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 |
| JP2025516647A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| JP2025538876A (ja) | 2022-11-24 | 2025-12-02 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ |
| WO2024208187A1 (zh) * | 2023-04-03 | 2024-10-10 | 上海复星医药（集团）股份有限公司 | 氮杂芳基化合物及其作为lsd1抑制剂的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432975B1 (en) * | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US7087614B2 (en) * | 2001-06-19 | 2006-08-08 | Bristol-Myers Squibb Co. | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
| DK2316831T3 (da) | 2002-11-21 | 2013-06-10 | Novartis Ag | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer |
| WO2004048364A1 (en) * | 2002-11-22 | 2004-06-10 | Merck & Co., Inc. | 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists |
| EP1694670A1 (en) * | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Pyrazine derivatives as effective compounds against infectious diseases |
| CA2560346A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| FR2896800B1 (fr) * | 2006-01-30 | 2008-04-11 | Servier Lab | Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AR072845A1 (es) * | 2008-07-29 | 2010-09-22 | Boehringer Ingelheim Int | 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas. |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| AU2010337891B2 (en) * | 2009-12-31 | 2015-07-02 | Piramal Enterprises Limited | Inhibitors of diacylglycerol acyl transferase |
| CN102985402B (zh) | 2010-04-20 | 2015-04-29 | 罗马大学 | 反苯环丙胺衍生物作为组蛋白去甲基酶lsd1和/或lsd2的抑制剂 |
| WO2012013727A1 (en) * | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| KR101351919B1 (ko) | 2012-05-23 | 2014-01-24 | 현대모비스 주식회사 | 차선 유지 보조 시스템 및 방법 |
| WO2014085613A1 (en) | 2012-11-30 | 2014-06-05 | Mccord Darlene E | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
| AR098203A1 (es) | 2013-11-13 | 2016-05-18 | Dow Global Technologies Llc | Reactivo de ensayo de formaldehído |
| SMT202300014T1 (it) * | 2013-12-11 | 2023-05-12 | Celgene Quanticel Research Inc | Inibitori della demetilasi lisina-specifica-1 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| KR102476459B1 (ko) * | 2014-09-05 | 2022-12-09 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
-
2015
- 2015-09-03 KR KR1020177009066A patent/KR102476459B1/ko active Active
- 2015-09-03 CN CN201580059765.5A patent/CN107074787B/zh not_active Expired - Fee Related
- 2015-09-03 CA CA2960188A patent/CA2960188A1/en active Pending
- 2015-09-03 SG SG10202008486SA patent/SG10202008486SA/en unknown
- 2015-09-03 CN CN202011074135.4A patent/CN112125901A/zh active Pending
- 2015-09-03 ES ES15838524T patent/ES2935114T3/es active Active
- 2015-09-03 JP JP2017512320A patent/JP6692350B2/ja not_active Expired - Fee Related
- 2015-09-03 WO PCT/US2015/048429 patent/WO2016037005A1/en not_active Ceased
- 2015-09-03 AU AU2015311805A patent/AU2015311805B2/en not_active Ceased
- 2015-09-03 US US14/845,120 patent/US9822119B2/en active Active
- 2015-09-03 EA EA201790376A patent/EA201790376A1/ru unknown
- 2015-09-03 EP EP15838524.5A patent/EP3189038B1/en active Active
- 2015-09-03 MX MX2017002824A patent/MX381597B/es unknown
- 2015-09-03 BR BR112017004334A patent/BR112017004334A2/pt active Search and Examination
- 2015-09-03 SG SG11201701683XA patent/SG11201701683XA/en unknown
-
2017
- 2017-03-01 IL IL250876A patent/IL250876B/en unknown
- 2017-03-03 CL CL2017000521A patent/CL2017000521A1/es unknown
- 2017-03-03 EC ECIEPI201713466A patent/ECSP17013466A/es unknown
- 2017-03-06 CO CONC2017/0002191A patent/CO2017002191A2/es unknown
- 2017-10-02 US US15/723,050 patent/US10543198B2/en not_active Expired - Fee Related
-
2019
- 2019-12-05 US US16/705,135 patent/US10864202B2/en active Active
-
2020
- 2020-04-14 JP JP2020072573A patent/JP6983273B2/ja not_active Expired - Fee Related
- 2020-06-26 AU AU2020204287A patent/AU2020204287A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527561A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2017519781A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2017514830A5 (enExample) | ||
| EA201992884A2 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2017521407A5 (enExample) | ||
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| JP2017523152A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| BR112015021027A2 (pt) | compostos terapêuticos | |
| JP2016522172A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| CY1118135T1 (el) | Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson | |
| JP2016515560A5 (enExample) | ||
| EA201691629A1 (ru) | Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| JP2016514159A5 (enExample) | ||
| JP2019510810A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| MX387207B (es) | Inhibidores de proteína quinasa, método de preparación y su uso médico. |